EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSRBIG00000038164
Gene Symbol: TP53
4 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosinase

Ensembl ID : ENSRBIG00000040657
Gene Symbol: TYR
4 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Hydroxylase

Ensembl ID : ENSRBIG00000033743
Gene Symbol: TH
4 Cross references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Kinase 2

Ensembl ID : ENSRBIG00000035551
Gene Symbol: TYK2
4 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSRBIG00000017224
Gene Symbol: TIE1
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine-Protein Kinase Syk-Like

Ensembl ID : ENSRBIG00000040470
Gene Symbol: LOC108516810
2 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Uncharacterized Loc108523015

Ensembl ID : ENSRBIG00000040202
Gene Symbol: LOC108523015
2 Cross references
23 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vascular Endothelial Growth Factor A

Ensembl ID : ENSRBIG00000041235
Gene Symbol: VEGFA
4 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vasopressin V2 Receptor-Like

Ensembl ID : ENSRBIG00000034619
Gene Symbol: LOC108535070
2 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vitamin D Receptor

Ensembl ID : ENSRBIG00000032268
Gene Symbol: VDR
4 Cross references
458 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSRBIG00000038158
Gene Symbol: VKORC1
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Xanthine Dehydrogenase

Ensembl ID : ENSRBIG00000038614
Gene Symbol: XDH
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).